Correlation analysis of FGF-2,Lp-PLA2 and IGF-1 levels and disease severity in patients with diabetic foot

doi:10.3969/j.issn.1673-8640.2022.09.005

Abstract

Abstract:

Objective To investigate the changes of serum fibroblast growth factor 2（FGF-2）,lipoprotein-related phospholipase A2（Lp-PLA2） and insulin-like growth factor-1（IGF-1） levels in patients with diabetic foot and the correlation with disease severity. Methods A total of 120 diabetic foot patients were enrolled as diabetic foot group. According to the Wagner classification,the diabetic foot patients were classified into grade 0-1 group（40 cases） and grade 2-3 group（48 cases） and grade 4-5 group（32 cases）. Totally,60 type 2 diabetes mellitus（T2DM）patients were enrolled as T2DM group,and 60 healthy subjects were enrolled as control group. The changes of serum FGF-2,Lp-PLA2 and IGF-1 levels were evaluated,and Spearman method was used to analyze the correlation between the above indicators and the degree of diabetic foot disease. Results The levels of serum FGF-2 and Lp-PLA2 in control group,T2DM group and diabetic foot group were increased in turn（P<0.05）,and the level of serum IGF-1 was decreased in turn（P<0.05）. In diabetic foot patients,the levels of serum FGF-2 and Lp-PLA2 in grade 0-1 group,grade 2-3 group and grade 4-5 group were increased in turn（P<0.05）,while serum IGF-1 level was decreased in turn（P<0.05）. Serum FGF-2 and Lp-PLA2 levels were positively correlated with Wagner grade（r values were 0.652 and 0.665,P<0.05）,and serum IGF-1 level was negatively correlated with Wagner grade（r=-0.643,P<0.05）. Conclusions Serum FGF-2,Lp-PLA2 and IGF-1 levels are closely related to the disease severity of diabetic foot.

Key words: Fibroblast growth factor 2, Lipoprotein-related phospholipase A2, Insulin-like growth factor-1, Diabetic foot

CLC Number:

R446.1

ZHANG Cheng, FEI Chunxia, FU Lin, GAO Chenfei, NI Dongying. Correlation analysis of FGF-2,Lp-PLA2 and IGF-1 levels and disease severity in patients with diabetic foot[J]. Laboratory Medicine, 2022, 37(9): 826-830.

Figures/Tables 6

References 17

[1]	刘春林, 徐波, 陈弟, 等. 感染性糖尿病足病原菌分布及耐药性分析[J]. 检验医学, 2019, 34(6):513-517.
[2]	LAURI C, LEONE A, CAVALLINI M, et al. Diabetic foot infections:the diagnostic challenges[J]. J Clin Med, 2020, 9(6):1779. DOI URL
[3]	DONG J, CHEN L, ZHANG Y, et al. Mast cells in diabetes and diabetic wound healing[J]. Adv Ther, 2020, 37(11):4519-4537. DOI URL
[4]	杨宏芳, 王晓慧. IGF-1、IGF-1结合蛋白3在运动防治肥胖、糖尿病和心血管疾病中的作用[J]. 生理科学进展, 2018, 49(3):193-196.
[5]	WAGNER FW Jr. The dysvascular foot:a system for diagnosis and treatment[J]. Foot Ankle, 1981, 2(2):64-122. DOI URL
[6]	糖尿病足诊治指南[J]. 介入放射学杂志, 2013, 22(9):705-708.
[7]	中国2型糖尿病防治指南(2013年版)[J]. 中华糖尿病杂志, 2014, 6(7):447-498.
[8]	裴翔, 欧阳茹, 陈铅琴. 2型糖尿病患者血清胆红素水平与糖尿病足的相关性[J]. 国际内分泌代谢杂志, 2020, 40(2):81-86.
[9]	潘晔, 高倩, 章文俊, 等. 胰岛素联合丹红注射液对糖尿病足患者足背血流动力学、血清炎症标记物和内皮功能的影响[J]. 中华全科医学, 2018, 16(8):1308-1310.
[10]	PUSPASARI A, HARIJANTI K, SOEBADI B, et al. Effects of topical application of propolis extract on fibroblast growth factor-2 and fibroblast expression in the traumatic ulcers of diabetic Rattus norvegicus[J]. J Oral Maxillofac Pathol, 2018, 22(1):54-58. DOI URL
[11]	钱超, 陈恬, 余建华, 等. 炎症因子Lp-PLA2、IL-18与糖尿病足溃疡的相关性研究[J]. 国际检验医学杂志, 2020, 41(2):163-167.
[12]	HESSE D, TROST J, SCHÄFER N, et al. Effect of adipocyte-derived IGF-I on adipose tissue mass and glucose metabolism in the berlin fat mouse[J]. Growth Factors, 2018, 36(1-2):78-88. DOI PMID
[13]	LIN M J, LU M C, CHAN Y C, et al. An insulin-like growth factor-1 conjugated Bombyx mori silk fibroin film for diabetic wound healing:fabrication,physicochemical property characterization,and dosage optimization in vitro and in vivo[J]. Pharmaceutics, 2021, 13(9):1459. DOI URL
[14]	宋登华, 王进, 孙家忠. 成纤维细胞生长因子2和血管细胞黏附分子-1与糖尿病足分级相关性分析[J]. 河北医药, 2016, 38(5):698-700.
[15]	WANG G H, JIN J, LIU Y Q, et al. The changes of Lp-PLA2 in patients with gestational diabetes and its clinical significance[J]. Medicine(Baltimore), 2021, 100(30):e26786.
[16]	尚涛, 任艳丽, 李静, 等. 重组人生长激素治疗前后糖尿病足患者血清中IGF-1、IGFBP-3和血浆蛋白水平的变化及其意义[J]. 吉林大学学报(医学版), 2017, 43(6):1209-1214.
[17]	张慧, 蔡俊玮, 李敏, 等. 糖尿病足患者血清IGF-1、IL-12、TIMP-1的表达水平及其与Wanger分级的相关性[J]. 医学综述, 2020, 26(22):4572-4576.

组别	例数	糖尿病病程/年	HbA_lc/%	TC/（mmol/L）	HDL-C/（mmol/L）	LDL-C/（mmol/L）
正常对照组	60		5.13±0.72	4.69±0.56	1.50±0.24	2.95±0.53
T2DM组	60	7.84±2.46	9.23±2.73^*	4.58±0.52	1.17±0.25^*	3.18±0.46^*
糖尿病足组	120	10.56±2.83^#	9.84±2.81^*	4.71±0.59	1.01±0.22^*#	3.24±0.37^*
统计值		5.619	78.062	1.094	88.602	8.945
P值		0.000	0.000	0.337	0.000	0.000

组别	例数	糖尿病病程/年	HbA_lc/%	TC/（mmol/L）	HDL-C/（mmol/L）	LDL-C/（mmol/L）
正常对照组	60		5.13±0.72	4.69±0.56	1.50±0.24	2.95±0.53
T2DM组	60	7.84±2.46	9.23±2.73^*	4.58±0.52	1.17±0.25^*	3.18±0.46^*
糖尿病足组	120	10.56±2.83^#	9.84±2.81^*	4.71±0.59	1.01±0.22^*#	3.24±0.37^*
统计值		5.619	78.062	1.094	88.602	8.945
P值		0.000	0.000	0.337	0.000	0.000

组别	例数	FGF-2/（ng/mL）	Lp-PLA2/（ng/mL）	IGF-1/（ng/mL）
正常对照组	60	4.64±1.11	124.69±31.13	143.92±38.28
T2DM组	60	10.53±2.84^*	240.69±57.15^*	86.22±22.27^*
糖尿病足组	120	17.17±5.22^*#	316.77±79.46^*#	58.52±16.71^*#
F值		204.835	175.441	232.176
P值		0.000	0.000	0.000

组别	例数	FGF-2/（ng/mL）	Lp-PLA2/（ng/mL）	IGF-1/（ng/mL）
正常对照组	60	4.64±1.11	124.69±31.13	143.92±38.28
T2DM组	60	10.53±2.84^*	240.69±57.15^*	86.22±22.27^*
糖尿病足组	120	17.17±5.22^*#	316.77±79.46^*#	58.52±16.71^*#
F值		204.835	175.441	232.176
P值		0.000	0.000	0.000

组别	例数	FGF-2/（ng/mL）	Lp-PLA2/（ng/mL）	IGF-1/（ng/mL）
0~1级组	40	13.51±3.59	255.73±48.95	72.22±14.68
2~3级组	48	16.58±4.19^*	316.94±62.94^*	56.33±13.02^*
4~5级组	32	22.64±3.65^*#	392.81±66.64^*#	44.68±9.80^*#
F值		50.714	46.832	41.913
P值		0.000	0.000	0.000